Close
SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

International Stem Cell Corporation Strengthens Intellectual Property Portfolio
[February 15, 2013]

International Stem Cell Corporation Strengthens Intellectual Property Portfolio

CARLSBAD, CA, Feb 15, 2013 (MARKETWIRE via COMTEX) -- International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company, today announced amendments to the license agreements with Advanced Cell Technology, Inc.

The license agreements, first entered into in 2004 and amended in 2005, granted ISCO access to a range of ACT's patents and patent applications for the use of various technologies in a limited set of human tissues.

The amendments extend ISCO's existing rights in the area of parthenogenesis, and the therapeutic use of parthenogenetically derived stem cells for treating any human diseases. Pursuant to the amended agreements ISCO now has an exclusive world-wide license to ACT's patents and applications covering the uses of parthenogenetically derived stem cells in generating human tissue.


"We're excited to have extended our portfolio of intellectual property which not only allows us to develop new therapeutic and business opportunities, but also makes the possibility of partnering with big pharma practical," commented Dr. Andrey Semechkin, CEO and Co-Chairman of ISCO.

About International Stem Cell Corporation International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products.

ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).

More information is available at www.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp BzID=1468&to=ea&s=0 To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell Safe harbor statement Statements pertaining to anticipated developments, the potential use of technologies to develop therapeutic products, potential strategic partnerships and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects" or "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contacts: International Stem Cell Corporation Dr. Simon Craw Executive Vice President Phone: 760-940-6383 Email: ir@intlstemcell.com Investor Relations: MZ Group Mark McPartland Senior Vice President Phone: 212-301-7130 Email: markmcp@mzgroup.us Web: www.mzgroup.com SOURCE: International Stem Cell Corporation mailto:ir@intlstemcell.com mailto:markmcp@mzgroup.us http://www.mzgroup.com/

[ Back To TMCnet.com's Homepage ]





LATEST VIDEOS

DOWNLOAD CENTER

UPCOMING WEBINARS

MOST POPULAR STORIES





Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.